Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
about
Risk Stratification in Differentiated Thyroid Cancer: An Ongoing ProcessTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaThe thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerEvaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications.Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases.Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's ThyroiditisBRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinomaLangerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying metastatic thyroid papillary carcinoma.Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patientsAssociation between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinomaSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialBRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules.Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancerAssociation of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case ReportMutational Analysis in Pediatric Thyroid Cancer and Correlations with Age, Ethnicity, and Clinical Presentation.A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.Molecular cytopathology for thyroid nodules: A review of methodology and test performance.Response to therapy of papillary thyroid cancer of known BRAF status.Surgical considerations for papillary thyroid microcarcinomas.Mutation profile of differentiated thyroid tumours in an Australian urban population.A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation.Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.Lack of Association of B-type Raf Kinase V600E Mutation with High-risk Tumor Features and Adverse Outcome in Conventional and Follicular Variants of Papillary Thyroid Carcinoma.Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro- Clinically Node Negative Papillary Thyroid Carcinoma.Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.BRAF V600E mutational status in pediatric thyroid cancer.Long-term outcomes of follicular variant vs classic papillary thyroid carcinoma
P2860
Q26765083-E00F5E61-78F8-4C03-BAD6-F77796D71C56Q26853261-25DEFFD0-4355-4797-946D-1F238ABA862EQ30364216-BA09FEB8-6A7C-4723-A8EB-37E3E0847199Q30367068-0B27C029-E233-45F5-9B2D-E62AD7F6A712Q33821945-DE144FF7-6DF4-4EB4-A0E3-3A9850163C8DQ33837093-30749706-A5CB-4835-BC65-0B2901624975Q33875906-381E311A-C1BA-48DA-86A9-38A7B4B32AE5Q33884794-DFD6E88B-995E-4BF0-8FFC-31769BEFF5A8Q34103836-AD550866-01E5-4AAB-AE02-58EBF48ED6EEQ34318833-C6A32243-1905-4CF0-ABB8-99142A0FBD25Q34366295-35A47101-3FA0-4280-96E5-C200A70CDE70Q34388349-95CA1849-8F01-49E6-962F-EFE754489E67Q34637861-CFAC6757-9971-4EC7-BE1B-1852D3FDD886Q35145064-B804C98D-CA0F-487D-BB00-4ABE8289512DQ35195766-F257FA68-8A1A-498A-B52B-480FCEB3368FQ35755353-DFB621B8-FD7E-4A62-8019-E7C804FCB7DAQ35758471-DCDC2934-DEAF-4A39-AA98-618C2A469A1DQ35908104-231B2B17-7D7A-43D4-8869-8E892DA3A928Q36339926-9E2901D8-642C-49E6-81E4-725224B6D94CQ36565803-8F3C0E75-3B17-46F0-AA2A-D991A88F7AE0Q37175455-8C179594-61C4-475D-86B5-692FEC4344A8Q37725502-4E84FB45-1264-4D2D-9F8F-BDEA19DD2E24Q38194099-31A41A25-957E-4979-A0B1-97304F5D98C9Q38582698-F77CCBC7-EBCB-4EEA-A825-5D1EDEC588DFQ38674063-9994A7E7-97DF-418A-A8DF-960F6E485112Q39312867-0A8C5342-8DA2-4E1F-AE6F-127CA9EB8EA3Q40195630-83535D9B-1CCC-42F6-A5F5-E793FBA2EB3FQ40619094-C5C83A82-3981-41E0-9AAC-7D1A3D0AEDE5Q41156932-51D4B06E-982D-480A-A9F3-A9A4B5BAB080Q41180701-2795B6F2-1C36-4160-B417-2BEF14B3FB40Q41665358-6730490A-5A14-478E-8BA1-DB9D2660FA1AQ42372581-1C7EC0F7-49FD-44D3-AA97-C53AAF4A3A5CQ47646209-C7B7384F-50C2-44A9-AA8F-E7128DC036EFQ49853776-C741EFEA-4864-4DFB-8781-E6B97A45C1EAQ52911465-0FFDCD53-454E-4375-AC05-8FC0296A26ABQ54364096-F8BD21B0-1AB2-4334-BCC6-149554265707Q57818908-C21BB8EE-0109-4CE7-8DDC-7BB177E3BFF6
P2860
Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@ast
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@en
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@nl
type
label
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@ast
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@en
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@nl
prefLabel
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@ast
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@en
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@nl
P2093
P1476
Lack of association of BRAF mu ...... ia, San Francisco, experience.
@en
P2093
Alan Bostrom
Annemieke van Zante
Christopher Gouveia
James P Grenert
Lisa A Orloff
Nhu Thuy Can
P304
P356
10.1001/JAMAOTO.2013.4501
P407
P577
2013-11-01T00:00:00Z